TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04768075
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT04768075
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04768075
Drug: Albumin paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT06202521
Drug: CX-4945 (SARS-CoV-2 domain)
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
Study: NCT06202521
Drug: Placebo (SARS-CoV-2 domain)
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage and frequency is the same as active drug.
Study: NCT06231758
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism
Study: NCT06202521
Drug: CX-4945 (Influenza virus domain)
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
Study: NCT06202521
Drug: Placebo (Influenza virus domain)
Normalized name: influenza A virus
DrugBank: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated) (DB10596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage and frequency is the same as active drug.
Study: NCT05447910
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05992077
Drug: Sofosbuvir/Daclatasvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
Study: NCT05942300
Drug: CPI-0209
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
Study: NCT05942300
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
Study: NCT05083780
Drug: Chlorphenesin Carbamate, Hydroxychloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.
Study: NCT05263492
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib once a day by mouth every day
Study: NCT05263492
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
Study: NCT05371301
Drug: Paclitaxel, Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1
Study: NCT06487416
Drug: Tiotropium Bromide Inhalation Powder
Normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
Study: NCT05432375
Drug: Tinostamustine
Normalized name: Tinostamustine
DrugBank: Tinostamustine (DB15147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion given over 60 minutes
Study: NCT05124691
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 400mg single dose
Study: NCT05586971
Drug: Tigulixostat
Normalized name: Tigulixostat
DrugBank: Tigulixostat (DB18799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthine Oxidase Inhibitor
Study: NCT05586971
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xanthine Oxidase Inhibitor
Study: NCT05928000
Drug: Bulevirtide
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: BulevIrtide treatment in patients with chronic hepatitis D
Study: NCT05709106
Drug: Rimegepant 75 MG
Normalized name: rimegepant 75 MG
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
Study: NCT06341101
Drug: Perindopril
Normalized name: Perindopril
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In case of side effects Perindopril will be replaced by Valsartan
Study: NCT04996771
Drug: Surufatinib,Etoposide,Cisplatin,Toripalimab
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed.
Study: NCT04996771
Drug: Surufatinib,Etoposide,Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed.
Study: NCT05991700
Drug: Freeze-Dried California Table Grape
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
DrugBank: Grape (DB10533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
Study: NCT06216886
Drug: Sodium Chloride 0.9% for Injection, Preservative Free
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
Study: NCT05446129
Drug: Ezabenlimab
Normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezabenlimab
Study: NCT05446129
Drug: BI 765063
Normalized name: BI-765063
DrugBank: BI-765063 (DB17482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 765063
Study: NCT05446129
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab
Study: NCT05049850
Drug: Imlifidase
Normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.
Study: NCT04634799
Drug: TM5614
Normalized name: TM5614
DrugBank: TM5614 (DB16516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
Study: NCT03847311
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
Study: NCT06258174
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06096779
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle.
Study: NCT06096779
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21-day cycle.
Study: NCT06431256
Drug: HLD200 methylphenidate hydrochloride capsules
Normalized name: Methylphenidate Hydrochloride Extended-Release Capsules
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doses: 20mg capsules
Study: NCT06400511
Drug: Pimecrolimus 0.3% Ophthalmic Ointment
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.
Study: NCT05553314
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients randomized to carvedilol group will receive carvedilol-SR.
Study: NCT05050149
Drug: PTX-022
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
Study: NCT06557850
Drug: Lu AG22515
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT06579105
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3-14 mg tablets of Semaglutide
Study: NCT06033612
Drug: RV299
Normalized name: Ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Suspension
Study: NCT06033612
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pre-filled oral syringe
Study: NCT06203236
Drug: Furosemide 20 MG
Normalized name: furosemide 20 MG
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation.
Study: NCT06149793
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium glucose co-transporter 2 inhibitor
Study: NCT05537896
Drug: Eravacycline
Normalized name: Eravacycline
DrugBank: Eravacycline (DB12329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC \>500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)
Study: NCT05711394
Drug: Atogepant
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05711394
Drug: Placebo-Matching Atogepant
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06434519
Drug: Metronidazole cream
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After application of one of the moisturizers under investigation in this study to the right side of the patient's face, x5 tape strips will be collected from the left side of a patient's face. These will provide negative controls for quantitation of metronidazole in the stratum corneum. Then, 0.5 mL of a 1% metronidazole cream will be applied to both the right and left sides of a patient's face with clean gloves to prevent cross contamination. Tapes strips x5 will subsequently be collected from the left and right sides of the face at 1 hour and 4 hour time points to assess penetrance of metronidazole through the stratum corneum.
Study: NCT05743907
Drug: DA-2811
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-2811 Group: DA-2811 + Forxiga placebo
Study: NCT05743907
Drug: Forxiga
Normalized name: Farxiga
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Forxiga Group: Forxiga + DA-2811 placebo
Study: NCT04748601
Drug: Qudexy XR
Normalized name: Qudexy XR Sprinkle
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extended-Release Capsule
Study: NCT05303987
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given.
Study: NCT05303987
Drug: Dexmedetomidine sedation
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given.
Study: NCT05971121
Drug: ciprofol
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol were used for sedation in ICU hypotensive patients
Study: NCT05567315
Drug: local anaesthetic injection
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
Study: NCT04839224
Drug: carbogen
Normalized name: carbogen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
Study: NCT04839224
Drug: phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Study: NCT05934942
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1358894
Study: NCT05552339
Drug: Finerenone (Kerendia, BAY94-8862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Following the physicians' decision.
Study: NCT05552339
Drug: Type 2 DM drugs
Normalized name: alpha-amylase A type 1-2
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the physicians' decision
Study: NCT06453915
Drug: 18F-DPA-714
Normalized name: DPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: positron emission tomography scan using 18F-DPA-714 as an imaging tracer.
Study: NCT06453915
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: positron emission tomography scan using 18F-FDG as an imaging tracer.
Study: NCT06315205
Drug: Letrozole LEBE 75 mg
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg
Study: NCT06315205
Drug: Letrozole LEBE 150 mg
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg
Study: NCT06315205
Drug: Letrozole LEBE 225 mg
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg
Study: NCT05645757
Drug: Ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics
Study: NCT05645757
Drug: WCK 6777
Normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of ertapenem (ERT) and zidebactam (ZID)
Study: NCT05645757
Drug: Zidebactam
Normalized name: Zidebactam
DrugBank: Zidebactam (DB13090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class
Study: NCT05027568
Drug: Nab paclitaxel / gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given in combination with IOA-289
Study: NCT05687123
Drug: Lutetium Lu 177 Dotatate
Normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05687123
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04973605
Drug: Sonrotoclax
Normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally daily
Study: NCT04973605
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once weekly either orally or intravenously
Study: NCT04973605
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously weekly
Study: NCT04973605
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously weekly
Study: NCT04973605
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally daily
Study: NCT06511791
Drug: FE 999302
Normalized name: Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
Study: NCT06511791
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
Study: NCT06550609
Drug: Miltefosine Oral Capsule
Normalized name: miltefosine Oral Capsule
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine 3 pill per day during 28 days AND pentamidine inhaled 300 mg / d during 10 dosis
Study: NCT04971031
Drug: Reproxalap Ophthalmic Solution (0.25%)
Normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
Study: NCT04971031
Drug: Vehicle Ophthalmic Solution
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
Study: NCT05824091
Drug: MK-7762 (TBD09)
Normalized name: vitamin MK 7
DrugBank: MK-7622 (DB12897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
Study: NCT06561087
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by injections
Study: NCT06559826
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following screening and baseline assessments, individuals randomized to KAP will undergo a preparatory session prior to the first day of dosing. Participants will complete a sequence of four to five intramuscular (IM) ketamine assisted therapy sessions.
Study: NCT05070858
Drug: Pozelimab + Cemdisiran
Normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration as described in the protocol
Study: NCT05070858
Drug: Cemdisiran
Normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration as described in the protocol
Study: NCT05070858
Drug: Pozelimab
Normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration as described in the protocol
Study: NCT06507371
Drug: PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody (Tislelizumab): 200mg d1 q3w
Study: NCT06507371
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study: NCT05726864
Drug: ELI-002 7P
Normalized name: eli-cel
DrugBank: Elivaldogene autotemcel (DB16746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)